Grifols (GRFS) Cash from Investing Activities Growth (3y) (2013 - 2020)
Grifols (GRFS) Cash from Investing Activities Growth (3y) (2013 - 2020) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 33.51% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -51.98% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 21.19% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -43.40% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -77.58% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -39.19% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -177.73% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 27.70% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 83.15% |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -27.30% |
| Dec 31, 2019 | -53.53% |
| Dec 31, 2018 | 37.09% |
| Jun 30, 2018 | -36.08% |
| Mar 31, 2018 | 31.30% |
| Dec 31, 2017 | 183.32% |
| Jun 30, 2017 | 26.51% |
| Mar 31, 2017 | 4.58% |
| Dec 31, 2016 | -47.99% |
| Sep 30, 2016 | -127.15% |
| Dec 31, 2015 | -182.62% |
| Sep 30, 2015 | 68.94% |
| Jun 30, 2015 | 727.86% |
| Mar 31, 2015 | -1,804.80% |
| Dec 31, 2014 | 61.45% |
| Sep 30, 2014 | -6.98% |
| Jun 30, 2014 | -16.43% |
| Mar 31, 2014 | 322.02% |
| Dec 31, 2013 | -27.07% |
| Sep 30, 2013 | 64.75% |